RGCC International

26/01/2026

Dr. Clayton Bell, Functional & Integrative Medicine Physician, shares how he incorporates RGCC testing into his clinical decision-making to help guide personalized treatment approaches.

By using the Onconomics panels, Dr. Bell gains insights that support treatment planning, helping physicians evaluate potential responsiveness to chemotherapy agents, immunotherapies, and hormone-blocking therapies for each individual patient.

Watch the full interview:
📽️ youtube.com/watch?v=98GK0V5OI3U&t=7s

22/01/2026

🌍 Cervical remains a global health challenge, with approximately 660,000 new cases diagnosed worldwide each year, the majority occurring in middle- and low-income regions. These disparities largely reflect unequal access to vaccination (one of the main risk factors for cervical cancer), cervical screening, timely treatment, and broader social and economic determinants of health.

Expanding access to prevention and early detection has the potential to significantly reduce incidence and save lives.

🔗 Learn more about and treatment options: https://rgcc-international.com/patient-information/cervical-cancer-treatment/

19/01/2026

Circulating Tumor Cells (CTCs) are a key indicator of active in the body. Monitoring the CTC levels helps clinicians assess disease progression and evaluate treatment response.
A high CTC count may indicate an increased risk of recurrence, making regular CTC testing an essential part of managing cancer treatment.

👉 Learn more about tests >> https://rgcc-international.com/research-and-development/

15/01/2026

The Oncotrail RGCC test provides crucial information on the presence of circulating tumor cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific types of .

The Oncotrail RGCC test analyzes the markers for very specific types of cancer, including:

✔️ Breast cancer
✔️ Colon cancer
✔️ GI cancer
✔️ Melanoma cancer
✔️ Lung cancer
✔️ Sarcoma cancer
✔️ Prostate cancer

Learn more about the test here: rgcc-international.com/tests/oncotrail-rgcc/

13/01/2026

We are proud to share that, as part of our ongoing commitment to Corporate Social Responsibility, RGCC International has donated €15,000 to the Department of Pediatric Oncology and Hematology at Charité - University Medicine Berlin.

Funds from this donation will support Charité - Universitätsmedizin Berlin's pioneering research program, helping advance innovative immunotherapies for children battling cancer.

We remain committed to our CSR mission and will continue to support organizations and research programs that promote health, innovation, and well-being worldwide. To read the full press release, visit:

As part of its CSR activities, RGCC Donates €15,000 to Support CAR-T Cell Therapy Research at Charité – Universitätsmedizin Berlin

08/01/2026

Liquid biopsies are helping transform how treatment decisions are informed in care.

Dr. Clifford Fetters, MD, shares how testing supports physicians by providing insights from circulating tumor cells, helping guide decisions across chemotherapy, natural, and supportive approaches, tailored to the individual patient.

👉 Learn more about our testing approaches: rgcc-international.com/tests/

24/12/2025

As 2025 comes to a close, we extend our heartfelt gratitude to our partners, clinicians, and patients around the world.
May your holidays be filled with peace, health, and hope for the year ahead.
✨ Happy holidays from all of us at RGCC.

18/12/2025

🎉 Reflecting on a remarkable 2025 at RGCC!

As 2025 draws to a close, we take a moment to reflect on a year marked by scientific progress, collaboration, and continued commitment to advancing personalized oncology.

This year, strengthened its global presence through international gatherings, scientific conferences, and collaborative research initiatives that united leading oncologists, healthcare practitioners, and researchers from around the world. We also celebrated important milestones, including the launch of the InVyomma Plus test.

As we look ahead to 2026, we remain dedicated to expanding the frontiers of precision medicine and supporting clinicians in providing truly personalized cancer care.

15/12/2025

Have you read our recently published poster, “Cell fusion model to investigate a potential origin of circulating tumor cells”?

Presented last month at the 7th Advances in Circulating Cells Meeting in Thessaloniki, Greece, the study explores the cell fusion process, the merging of the membranes of two or more cells into one hybrid cell, which is associated with cancer initiation, progression, and metastasis. It particularly focuses on the fusion of and immune cells, which can create hybrid cells with unique properties, including drug resistance, immune evasion, and cancer progression. Therefore, the project aimed to establish an in vitro cell fusion model to investigate this important biological process.

📄 Explore the study and all our published research: rgcc-international.com/published-articles/

11/12/2025

We’re proud to share that in 2025, RGCC researchers published six scientific articles, further contributing to the global understanding of personalized oncology.

Our 2025 publications include:
📄 The continual problem of crossing survival curves in clinical trial analysis and methods for effectively addressing it: A narrative review
📄 Assessment of protein expression and enumeration of circulating tumor cells in various cancer types
📄 Cell fusion model to investigate a potential origin of circulating tumor cells
📄 Enumeration and immunophenotype of circulating tumor cells in colorectal cancer patients
📄 Second-line therapy adjustment for advanced pancreatic cancer using circulating tumor cells: Preliminary results
📄 Adjusting treatment strategies using circulating tumor cells: Preliminary results on metastatic colorectal cancer

Each study reflects our ongoing commitment to advancing cancer diagnostics, refining therapeutic strategies, and improving patient outcomes.

🔗 All publications are available on our website:

Experts in developing and providing personalised cancer genetic tests for doctors and patients, RGCC is a specialist medical genetics company based in Switzerland, with laboratories worldwide.

09/12/2025

🔬 New Study Highlights Breakthrough in Ovarian

A real‑world study shows that analysis can guide personalized treatment and improve outcomes for women with advanced or recurrent ovarian cancer. 📊 Using 's test, researchers analyzed CTC counts, biomarkers, chemosensitivity, and mRNA profiling, enabling physicians to tailor therapies more precisely and extend time on treatment. 💡These findings add to growing evidence that CTC‑guided approaches are shaping the future of precision medicine — reducing toxicity, improving survival, and transforming cancer care.

➡️ Find more info and the publication here: https://bit.ly/studyOC

04/12/2025

Throwback post!

Last August, our Founder & Director, Dr. Ioannis Papasotiriou, joined Samael Tejada and Dr. Christopher Davis, MD, on the Healthy Point of View Podcast.
During the discussion, Dr. Papasotiriou shared his thoughts on the sensitivity of personalized tests and how ’s advanced cancer screening tools are transforming early detection and personalized treatment strategies.

📺 Watch the full episode: https://bit.ly/rgcc-pod